249 related articles for article (PubMed ID: 22137923)
1. B-cell therapies in established rheumatoid arthritis.
Leandro MJ; Becerra-Fernandez E
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
[TBL] [Abstract][Full Text] [Related]
4. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
5. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
6. [Safety of rituximab in patients with rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of rheumatoid arthritis.
Schuna AA
Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
[TBL] [Abstract][Full Text] [Related]
9. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
10. Targeting the B cell in rheumatoid arthritis.
Cohen SB
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):553-63. PubMed ID: 20732652
[TBL] [Abstract][Full Text] [Related]
11. What is the role of rituximab in the treatment of rheumatoid arthritis?
Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Ann Rheum Dis; 2012 Mar; 71(3):374-7. PubMed ID: 21972242
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for rheumatoid arthritis.
Palylyk-Colwell E; McGahan L
Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
16. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
17. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
18. The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.
Brinkman IH; van de Laar MA; Jansen TL; van Roon EN
Expert Opin Drug Saf; 2011 Sep; 10(5):715-26. PubMed ID: 21401437
[TBL] [Abstract][Full Text] [Related]
19. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
20. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
